Aptamer-functionalized liposomes targeting HER2, CD44, and nucleolin have shown enhanced tumor selectivity, improved pharmacokinetics, and strong antitumor activity with reduced systemic toxicity. This evidence concerns the gene ERBB2 and neoplasm.